61702-15-6

Usage

Uses

Used in Pharmaceutical Research and Drug Development:
4-Propyl-pyridin-2-ylamine is used as a chemical intermediate for the synthesis of various pharmaceutical compounds due to its potential biological activities and versatility in chemical reactions.
Used in Cancer Treatment:
In the field of oncology, 4-Propyl-pyridin-2-ylamine is used as a potential therapeutic agent for the treatment of various types of cancer. Its ability to target and modulate specific cellular pathways makes it a promising candidate for cancer research and drug development.
Used in Central Nervous System Disorders:
4-Propyl-pyridin-2-ylamine is used as a potential treatment for central nervous system disorders due to its potential role in modulating neurotransmitter function in the brain. This makes it a candidate for drug development in the field of neuroscience, particularly for conditions such as Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders.
Used in Inflammation Management:
In the context of inflammation, 4-Propyl-pyridin-2-ylamine is used as a potential anti-inflammatory agent. Its capacity to modulate inflammatory responses and pathways positions it as a candidate for the development of drugs targeting inflammatory conditions such as arthritis, asthma, and other autoimmune diseases.

InChI:InChI=1/C8H12N2/c1-2-3-7-4-5-10-8(9)6-7/h4-6H,2-3H2,1H3,(H2,9,10)

Upstream product

• 30838-95-0 2-chloro-4-propylpyridine 
• 663614-88-8 4-n-propyl-2-pyridinecarbonitrile 
• 25813-87-0 4-propylpyridine-1-oxide 
• 1122-81-2 4-n-propylpyridine 

Downstream Products

• 1418307-27-3 N-(4-propylpyridin-2-yl)-4-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)benzamide 
• 1418307-29-5 (S)-4-(8-methyl-3-(piperidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(4-propylpyridin-2-yl)benzamide 
• 1418307-28-4 (S)-benzyl 2-(8-methyl-1-(4-(4-propylpyridin-2-ylcarbamoyl)phenyl)imidazo[1 ,5-a]pyrazin-3-yl)piperidine-1-carboxylate 
• 87999-87-9 4-propyl-pyridine-2-carboxylic acid 

Relevant academic research and scientific papers

INHIBITORS OF BRUTON'S TYROSINE KINASE

Disclosed herein are compounds that inhibit Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. In addition, reversible inhibitors of Btk are also described. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

QUINOLINE AND QUINAZOLINE COMPOUNDS

In some embodiments, the invention relates to quinazoline and quinoline compounds of Formula I: (I) or a pharmaceutically acceptable salt thereof, or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, in some embodiments, the present invention relates to quinazoline and quinoline compounds, pharmaceutical compositions thereof, and the use of the compounds and pharmaceutical compositions in the treatment of Bruton's tyrosine kinase (BTK) mediated disorders.

INHIBITORS OF BRUTON'S TYROSINE KINASE

Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. In addition, reversible inhibitors of Btk are also described. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

CARBINOL DERIVATIVES HAVING HETEROCYCLIC LINKER

[Object] It is to provide a novel LXRβ agonist useful as a preventative and/or therapeutic agent for atherosclerosis; arteriosclerosis such as those resulting from diabetes; dyslipidemia; hypercholesterolemia; lipid-related diseases; inflammatory diseases that are caused by inflammatory cytokines; skin diseases such as allergic skin diseases; diabetes; or Alzheimer's disease. [Solving Means] A carbinol compound represented by the following general formula (I) or salt thereof, or their solvate: (wherein, each V and W independently show N or C—R7; each X and Y independently show CH2, C═O, SO2, etc; Z shows CH or N; each R1, R2 and R7 independently show a hydrogen atom, C1-8 alkyl group, etc.; R3 shows C1-8 alkyl group; R4 shows an optionally substituted C6-10 aryl group or an optionally substituted 5- to 11-membered heterocyclic group; R5 and R6 show a hydrogen atom, etc.; L shows a C1-8 alkyl chain optionally substituted with an oxo group, etc.; and n shows any integer of 0 to 2.)

Substituted 2-aminopyridines as inhibitors of nitric oxide synthases.

A series of substituted 2-aminopyridines was prepared and evaluated as inhibitors of human nitric oxide synthases (NOS). 4,6-Disubstitution enhanced both potency and specificity for the inducible NOS with the most potent compound having an IC50 of 28 nM.

Biphenylmethane derivative and pharmacological use

The biphenylmethane derivative having the formula (I) is useful to prevent and treat hypertension and cardiac failure. STR1 in which R1 is hydrogen, an alkyl, a cycloalkyl, a halogenated alkyl, --S--R7, --SO2--R7, --C C--R7 or --(CH2)--OR7, R7 being hydrogen, an alkyl, a cycloalkyl or a halogenated alkyl, p being zero or 1, --A1=A2--A3=A4-- is CH=CH--CH=CH--, --N=CH--CH=CH--, --CH=N--CH=CH--, --CH=CH--N=CH--, --CH=CH--CH=N-- or --CH=N--CH=N--, R2 and R3 are each hydrogen, a halogen, a lower alkyl, a lower alkoxy, a carbamoyl or cyano, R4 is hydrogen or a lower alkyl, R5 is 1H-tetrazol-5-yl, carboxyl (--COOH) or a carboxylic ester and R6 is hydrogen, a halogen, hydroxyl or a lower alkoxy, or a pharmacologically acceptable salt thereof.